Skip survey header

Myeloma - Pre-Test

Updates in Multiple Myeloma

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

This activity is supported by an educational funding donation provided by Amgen, and unrestricted educational grants provided by Celgene Corporation and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Release date: July 28, 2017                         Estimated time to complete activity: 1.0 hours
Expiration date: July 28, 2018

Beth Faiman, PhD, MSN, APRN-BC, AOCN®
Cleveland Clinic

Activity Rationale and Purpose
Of the 1.6 million people who will be diagnosed with cancer in 2016, fewer than 10% will suffer from a rare form of blood cancer. Because these diseases are relatively rare compared to solid tumors, most providers in clinical practice will have limited exposure to these patients. Given the robust pace of scientific discovery and FDA approval over the last 3 years, oncology practitioners must maintain a wide knowledge base to effectively treat patients. The Advanced Practitioner takes on much of this role as an integral member of the collaborative practice team. This activity will help learners narrow the gap between clinical practice and newer treatment methodologies for multiple myeloma, including novel agents and the management of their potential side effects.

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:
• Identify the mechanism of action for novel agents used for the treatment of hematological malignancies including multiple myeloma
• List monitoring parameters for toxicities associated with newer agents used to treat multiple myeloma
• Describe the signs of early and serious toxicity that providers and patients need to be aware of when initiating therapy with new agents for multiple myeloma
• Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings
• Anticipate and identify potential adverse events that may be associated with newer targeted and immunotherapies and how such adverse events may be adequately addressed to optimize patient outcome
• Discuss the pivotal role and necessary expertise of the AP as a vital part of the inter-professional oncology/hematology team

Continuing Education


The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

A maximum of 1.0 contact hours may be earned for successful completion of this activity.


This knowledge-based accredited education lecture is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-9999-17-072-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Dr. Faiman has acted as a consultant, received honoraria from, and has served on the speakers’ bureau for Amgen, Bristol-Myers Squibb, Celgene, and Takeda.

Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Patti McLafferty has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Moshe C. Ornstein, MD, MA, Cleveland Clinic Taussig Cancer Institute, has nothing to disclose.

Annenberg Center for Health Sciences at Eisenhower
The staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Harborside Medical Education, and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To claim credit for this activity, participants must complete the pre-assessment, view the content, pass the post-assessment, and complete and submit an evaluation. Content is available on

Statement of Credit: Participants who successfully complete this activity (including correctly answering the one (1) question on the learning assessment and completing and submitting the evaluation form) will be able to download a statement of credit. Participants have three (3) attempts available to pass the assessment.